Despite the potential threat of tariffs, trade policy did not factor into the India-based CRDMO’s purchase of a Baltimore biologics site from Emergent BioSolutions.
More than 300 comments have been posted in response to a Department of Commerce investigation into the importation of certain pharmaceuticals and pharma ingredients.
CEO Padraig McDonnell contends that Biovectra’s capabilities are in the “sweet spot” of GLP-1s and complex chemistries, with strong medium- and long-term growth potential.
The Minnesota-based company is now being covered by William Blair analyst Max Smock who spoke with Pharma Manufacturing about Lifecore’s position in the CDMO landscape.
With a record number of FDA biosimilar approvals in 2024, CMOs specializing in biologics can expect to see higher biosimilar volumes, according to GlobalData.
PhRMA warned that President Trump’s executive order on most favored nation would jeopardize hundreds of billions of dollars in planned U.S. investments by its members.
The company warned that if the executive order goes into effect, Roche’s ability to invest $50 billion in its U.S. R&D and manufacturing sites will be in question.
CEO Bill Anderson said that the company has “considerable” production capabilities in both the U.S. and Europe but has no immediate plans to shift them.
CEO Christophe Weber said that the investment is not a new strategy and reflects the position of the U.S. as the world’s leading market for biopharma innovation.
The announcement comes after President Trump signed an executive order aimed at expediting the approval process for domestic pharmaceutical manufacturing facilities.
Expansions at sites in Le Mans and Mourenx, France have solidified the CDMO’s position in targeting the hot antibody-drug conjugate and peptide purification markets.
Dave Ricks said Lilly supports the administration’s goal of bringing pharma manufacturing back to the U.S. but doesn’t see tariffs as the “right mechanism” for reshoring.
CEO Albert Bourla said that President Trump’s threat of pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and R&D.
CEO Rob Michael told analysts that the company is investing more than $10 billion in the U.S. to support volume growth and expansion into new areas such as obesity.
The three Big Pharma companies on their earnings calls this week tried to reassure investors that they have the global footprints to mitigate the effects of tariffs.
The life sciences tools and services company said U.S.-China tariffs are expected to cut 2025 revenue by $400 million and adjusted operating income by $375 million.
Despite the widespread success of CAR T therapies, there have been challenging immunologic side effects such as cytokine release syndrome and neurotoxicity, which can now be mitigated...
The CDMO plans to build and expand small, medium, and large manufacturing facilities across Europe and the U.S. over the next three years to meet rising demand for peptides.
President Trump has threatened to impose tariffs on pharmaceuticals, as a Department of Commerce probe on drug imports gets underway. But analysts and stakeholders are skeptical...
While animal testing has been mandated for every drug since the 1930s, the drug development framework is changing — a long overdue and much needed change.
The agency has cited several drugmakers with warning letters, import alerts, and Form 483s for manufacturing lapses ranging from data integrity violations to sterility assurance...
Despite Trump pushing drugmakers to bring manufacturing back to the U.S., it remains unclear whether companies — other than Eli Lilly, J&J, and Novartis — will respond.
The CDMO, with 3,200 employees at 20 locations in the U.S., Europe and India, has a global footprint to help customers navigate their R&D and manufacturing challenges.
Despite Trump pushing drugmakers to bring manufacturing back to the U.S., it remains unclear whether companies — other than Eli Lilly, J&J, and Novartis — will respond.
The company says it is investing in areas across the value chain to ensure its customers continue to enjoy the benefits of a global network with local access.
